Company profile
Lipigon Pharmaceuticals company profile
Lipigon Pharmaceuticals is specialized in fat metabolism and develops new blood lipids. Lipigon is currently focusing on developing drugs directed against the enzyme lipoprotein lipase (LPL). People with low activity at LPL have a higher incidence of elevated blood fats and also related disorders such as insulin resistance and metabolic syndrome. Thanks to Lipigon's expertise in this area, AstraZeneca has chosen to enter into a cooperation agreement with the Company to develop LPL-based pharmaceuticals. Lipigon can receive up to $ 110 million in compensation at achieved milestones related to development and sales.
Business identity
- Website
- http://www.lipigon.se/
- Contact email
- [email protected]
- Phone number
- +46(0)705781768
- Operating status
- Active
- Company type
- For Profit
- Employee range
- 1-10 employees
- Revenue range
- $1M-$10M
- Founded
- 2010-01-01, Year
Headquarters
- Headquarters
- Umeå, Västerbotten, Sweden
- Postal code
- 90752
- Country code
- SE
- Continent
- Europe